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ABSTRACT 
The understanding of metabolic pathologies is made easy with the emergence of the 
most luring cytokine - Adiponectin, which is produced exclusively by adipocytes and 
which enhances insulin sensitivity and inhibits many steps in the inflammatory 
process by exerting its action through its receptors AdipoR1, AdipoR2, and T-
cadherin. AdipoR1 is expressed abundantly in muscle, whereas AdipoR2 is 
predominantly expressed in the liver. In liver, Adiponectin inhibits the expression of 
gluconeogenic enzymes and the rate of glucose production. In muscle, Adiponectin 
increases glucose transport and enhances fatty acid oxidation, partially due to 
activation of AMP kinase.  
These above physiological activities and many more are performed with the normal 
or high levels of Adiponectin in the blood whereas the decreased levels of the same 
leads to various metabolic disorders. The present article encompasses various 
researches and recent progress made in understanding the biological effects of 
Adiponectin. These studies confer Adiponectin’s role as biomarker and mediator in 
multiple systemic pathophysiologies, thereby establishing its clinical and 
therapeutic value in the conditions ranging from metabolic syndrome to 
malignancies. Also presented in this paper is the contribution of Ayurveda in the 
form of single herbal drugs which show the therapeutic modulation on Adiponectin. 
KEYWORDS: Adiponectin, Pathophysiology, Pleiotropic Biomarker, Ayurvedic herbs. 
INTRODUCTION 
The fascinating molecule and White 
Adipose Tissue Hormone, Adiponectin, is 
also known as Gelatin- Binding Protein-28 
(GBP28), ADIPO-Q, C1Q and Collagen 
Domain Containing,[1] Adipocyte 
Complement-Related Protein (ACRP30), or 
APM1.  
Adiponectin is reduced in the 
metabolic disorders.[2] Apart from causing 
metabolic dysfunction, Adiponectin 
deficiency may also contribute to Coronary 
Heart Disease, Steatohepatitis, Insulin 
Resistance, Nonalcoholic Fatty Liver Disease, 
and a wide array of cancers.[3] 
There are many emerging studies 
which highlight the clinical importance of 
Adiponectin in human pathologies of various 
metabolic diseases. Primarily 
Hypoadiponectemia was found to be 
associated with obesity and diabetes, 
indicating it’s relation to systemic insulin 
sensitivity and the ability to directly regulate 
whole body energy metabolism. In healthy 
lean humans, circulating Adiponectin levels 
range from 2-30 mg/L.[4] 
Adiponectin has attracted much 
attention lately because of its clinical 
importance, attributed to its anti-
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inflammatory, insulin sensitizing and 
antiatherogenic properties.[5] 
Adipose tissue is not simply an inert 
storage depot for lipids but is also an 
important endocrine organ that plays a vital 
role in the integration of endocrine, 
metabolic, and inflammatory functions to 
control energy homeostasis. Adipocytes 
secrete a variety of bioactive secretory 
proteins into the circulation which are 
collectively named as Adipocytokines which 
include Leptin, Tumor Necrosis Factor 
(TNF)-Α, Plasminogen-Activator Inhibitor 
Type 1 (PAI-1), Adipsin, Resistin and 
Adiponectin.  
Adiponectin, the gene product of the 
adipose tissue’s most abundant gene 
transcript 1 (apM1), is a novel and 
important member of the Adipocytokine 
family. Adiponectin cDNA was first isolated 
by large-scale random sequencing of the 
human adipose tissue cDNA library [6]. It is a 
collagen-like protein that is exclusively 
synthesized in white adipose tissue, induced 
during adipocyte differentiation, and 
circulates at relatively high concentrations 
in the serum.  
Adiponectin has been postulated to 
play an important role in the modulation of 
glucose and lipid metabolism in insulin-
sensitive tissues in both humans and 
animals. Decreased circulating Adiponectin 
levels have been demonstrated in genetic 
and diet-induced murine models of obesity, 
as well as in diet-induced forms of human 
obesity.[7] Low Adiponectin levels have also 
been strongly implicated in the development 
of insulin resistance in mouse models of 
both obesity and lipoatrophy. Plasma 
Adiponectin levels in diabetic subjects with 
coronary artery disease (CAD) are lower 
than in diabetic patients without CAD, 
suggesting that low Adiponectin levels are 
associated with an atherogenic lipid profile 
and improved levels of Adiponectin have 
anti-atherogenic properties.[8] In studies 
done on human aortic endothelial cells, 
Adiponectin has been shown to dose-
dependently decrease the surface expression 
of vascular adhesion molecules known to 
modulate endothelial inflammatory 
responses. It also inhibits proliferation of 
vascular smooth muscle cells and 
concentrates within the vascular intima of 
catheter-injured vessels.[9]  
The association of low Adiponectin 
levels with obesity, insulin resistance, CAD, 
and dyslipidemia indicates that this novel 
protein can be an important marker of the 
metabolic syndrome.[61]  
From the inferences of researches till 
date on Adiponectin, it is clear that the 
serum levels of Adiponectin are negatively / 
inversely related to the clinical 
manifestation of multiple diseases like DM 2, 
Obesity, CVD, NAFLD, Cancer, etc., 
encompassing different systems of the body. 
Hence, the very purpose in dealing the 
untoward clinical outputs of Adiponectin lies 
in improving the levels of Adiponectin either 
through natural or conservative methods.  
In this article we present the 
scientific appraisal of Adiponectin for its 
central role in the pathophysiology of 
multisystem diseases and the scientific 
update on some of the Ayurvedic herbs for 
their effect on the maintenance of the 
healthy levels of Adiponectin. The drugs 
reviewed herein are Haridra, Amalaki, 
Pippali, Pushkaramula, Guduchi, Musta and 
Aardraka, which are part of an Extra-mural 
research project on Pre-Diabetes done in 
N.I.A., Jaipur. 
STRUCTURE & FUNCTIONS OF 
ADIPONECTIN 
In 1995, P.E. Scherer, Lodish et al., 
identified a secretory protein from murine 
3T3-L1 adipocytes and named it Adipocyte 
complement-related protein of 30 kDa 
(Acrp30). It is a structural homolog to 
complement factor C1q and to a hibernation-
specific protein isolated from the plasma of 
Siberian chipmunks. It forms large homo-
oligomers that undergo a series of 
posttranslational modifications. Using the 
mRNA differential display technique, it was 
cloned and called adipoQ. Thus, a 
 Int. J. Ayur. Pharma Research, 2014; 2(5): 63-75  ISSN: 2322 - 0910 
 
 Available online at : http://ijapr.in Page 65 
description of the cDNA encoding 
Adiponectin was first reported.[10] 
In 1999, a group at Osaka University 
isolated the human adipose-specific 
transcript, the apM1 gene product, which 
was found to be a soluble matrix protein, 
and named it Adiponectin. It was identified 
as a distinct protein among the adipokines 
because the plasma concentration of 
Adiponectin decreases upon accumulation of 
visceral fat. 
Adiponectin is a protein hormone 
consisting 247 amino acids and the 
corresponding gene is found in chromosome 
3q27 (long (q) arm of chromosome 3 at 
position 27), which is considered to be a 
locus that is highly susceptible for the 
development of metabolic diseases. 
Adiponectin structurally is associated 
with the complement 1q (C1q) family and 
consists of a Carboxy terminal globular 
domain and an Amino terminal collagenous 
domain. The full length Adiponectin (fAd) 
consists of an N-terminal stalk made of 22 
collagen repeats and a highly conserved 
globular domain at the C-terminal. 
Proteolytic cleavage of fAd by leukocyte 
elastase produces smaller globular 
Adiponectin (C-terminal) fragments (gAd). 
Adiponectin receptors 1 (AdipoR1) and 2 
(AdipoR2) are expressed ubiquitously in 
most organs, especially in skeletal muscle in 
AdipoR1, and liver in AdipoR2.[4] 
HMW form is found to be inversely 
correlated in patients with different 
systemic diseases while the circulating LMW 
form remains unchanged. HMW forms have 
been shown to significantly improve 
circulating glucose in diabetic humans and 
animal models, suggesting that HMW is the 
most active form of Adiponectin. 
Furthermore, significant weight reduction in 
patients elevates the circulating HMW form 
of Adiponectin. 
The pharmacological effects of 
Adiponectin have been studied at animal, 
tissue, and cellular levels using a variety of 
recombinant Adiponectin products. It is 
possible that Adiponectin exists as variable 
protein complexes that exert different 
effects in various tissues. The globular head 
domain of Adiponectin has been shown to be 
more potent than the full-length form in 
ameliorating hyperglycemia and 
hyperinsulinemia in diet-induced and 
genetic forms of murine obesity and in 
decreasing elevated plasma free fatty acids 
in mice fed a high-fat meal or given 
intravenous intralipid injections.[11] 
In skeletal muscle of mice, 
Adiponectin has been shown to increase 
expression of the genes encoding proteins 
involved in fatty acid transport and 
oxidation, such as CD36, acyl-CoA oxidase, 
and uncoupling protein, resulting in 
enhanced fat combustion and energy 
dissipation.[12] 
In the liver, low doses of Adiponectin 
decreased the expression of proteins 
involved in fatty acid transport, such as 
CD36, leading to reduced fatty acid influx 
into the liver and hepatic triglyceride 
content. Improved hepatic insulin sensitivity 
occurred, leading the investigators to 
postulate that the primary effects of 
Adiponectin on muscle are to augment 
uptake and combustion of free fatty acids 
(FFAs), whereas decreased liver triglyceride 
content results from secondary reductions in 
serum FFA and triglyceride levels. 
Single nucleotide polymorphisms in 
the Adiponectin gene have been reported in 
humans. Some of these polymorphisms 
markedly reduce plasma Adiponectin levels 
and predispose the carriers to insulin 
resistance. I164T polymorphism is one such 
mutation (isoleucine is substituted by 
threonine at the 164th position) that is 
reported to be a causative factor for 
hypoadiponectemia and the development of 
type 2 diabetes. Furthermore, individuals 
with this mutation are highly susceptible for 
the development of hypertension and 
coronary artery disease, suggesting the 
protective role of Adiponectin against 
development of metabolic disease in 
humans. 
It can be deduced from the above 
discussion that the mechanism of action of 
Adiponectin principally involves Insulin-
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sensitizing actions, activation of PPARα & 
AMP kinase and Antiatherosclerotic actions 
leading to a myriad of protective roles in 
varied pathophysiologies.[13] 
PATHOPHYSIOLOGIES: PLEIOTROPIC 
ROLE OF ADIPONECTIN 
A continuous research on 
Adiponectin for over 2 decades has 
established its role as a biomarker in major 
pathophysiologies of human body. The 
pleiotropic role of Adiponectin is proved In-
Vivo and In-Vitro in Type II Diabetes, 
Obesity, Dyslipidaemias, Hypertension, 
Multiple Sclerosis (MS), Cancer, Non-
Alcoholic Fatty Liver Disease, Cardio 
Vascular Diseases and Inflammations etc., 
encompassing different organ systems of the 
body. 
 Adiponectin in Obesity and Type II 
Diabetes: Mediator of Insulin Action / 
Resistance. 
As Adiponectin is produced 
exclusively by the adipocyte, its 
concentration in the serum is affected by 
changes in adipose tissue mass. However, 
unlike most adipose-derived hormones and 
secreted proteins, Adiponectin mRNA and 
serum levels are decreased in obesity.[14], [15] 
And, Plasma levels of Adiponectin exhibit 
strong negative correlations with direct (via 
computerized tomography scan) and 
indirect (waist-to-hip ratio, waist 
circumference) measures of intra-abdominal 
fat (IAF) mass.[16], [17] 
The expression of the receptors 
AdipoR1 and AdipoR2 decline by 30% in the 
subcutaneous fat of obese individuals, while 
they normalize following weight loss. 
The most significant role played by 
Adiponectin is that of its insulin-sensitizing 
effect. Total Adiponectin, HMW Adiponectin, 
and HMW ratio are inversely related to 
homeostasis model assessment (HOMA) of 
Insulin Resistance Index. A strong 
correlation between Adiponectin and 
systemic insulin sensitivity has been well 
established both in vivo and in vitro in mice, 
other animals, and humans. 
In a study conducted on Pima Indians 
and Caucasians where the individuals have 
varied levels of glucose tolerance it is 
observed that decreased Adiponectin levels 
are closely related to the degree of Insulin 
Resistance and Hyperinsulinemia.[18] 
Adiponectin administration to 
rodents has been shown to increase insulin-
induced tyrosine phosphorylation of the 
insulin receptor in skeletal muscle in 
association with increased whole-body 
insulin sensitivity.12 Stimulation of glucose 
utilization and fatty acid oxidation in skeletal 
muscle and liver by Adiponectin may also 
have occurred through activation of 5′-AMP 
kinase. 
In experiments conducted by Berg et 
al.[19] intraperitoneal injection of 
mammalian-extracted full-length 
Adiponectin into fasting male wild-type mice 
and two models of type 1 diabetes—
insulinopenic nonobese diabetic and 
streptozotocin-induced diabetic mice—
produced a significant transient reduction of 
glucose levels. Adiponectin injection into a 
type 2 diabetic model (ob/ob mice) also 
lowered glucose levels. 
Circulating Adiponectin levels have 
been shown to decrease in parallel with 
progression of insulin resistance during 
development of type 2 diabetes in rhesus 
monkeys genetically predisposed to develop 
insulin resistance.[20] In this study, there was 
a negative correlation of Adiponectin levels 
with body weight and fasting insulin levels 
and a positive correlation with insulin-
stimulated glucose uptake (a marker of 
insulin sensitivity). In these monkeys, the 
decline in Adiponectin levels preceded overt 
hyperglycemia. 
Adipocyte insulin action or signal 
transduction rather than absolute levels of 
insulin may regulate Adiponectin secretion. 
In support of this contention, Bogan and 
Lodish 21 have shown that secretion of 
Adiponectin by 3T3-L1 adipocytes requires 
 Int. J. Ayur. Pharma Research, 2014; 2(5): 63-75  ISSN: 2322 - 0910 
 
 Available online at : http://ijapr.in Page 67 
phosphatidylinositol 3-kinase (PI-3K), a 
major intermediate of insulin signalling 
activity. Insulin-stimulated insulin receptor 
substrate 1 (IRS-1)-associated PI-3K activity 
has been shown to be decreased in 
adipocytes of type 2 diabetic subjects. Thus 
it is possible that the decreased adipocyte 
PI-3K activity in type 2 diabetic patients may 
contribute to the decreased Adiponectin 
levels. 
The connection between Adiponectin 
levels and insulin resistance has been 
further confirmed by data obtained from 
treatment with Thiazolidinediones (TZDs). 
TZDs are specific synthetic ligand activators 
of PPAR-γ (Peroxisome Proliferator-
Activated Receptor (PPAR)-γ is a ligand-
activated transcription factor and regulator 
of adipocyte differentiation and multiple 
adipocyte genes) that improve glucose 
tolerance and insulin sensitivity in muscle 
and fat tissue in type 2 diabetic patients. 
In support of an important role for 
PPAR-γ in regulation of Adiponectin 
synthesis, circulating Adiponectin levels 
were found by Combs et al.[18] to be 
suppressed fivefold in patients with severe 
insulin resistance in association with 
dominant-negative PPAR-γ mutations. Thus, 
induction of adipose tissue Adiponectin 
expression and consequent increases in 
circulating Adiponectin levels could 
potentially represent a novel potential 
mechanism for PPAR-γ-mediated 
enhancement of whole-body insulin 
sensitivity. 
Adiponectin is considered as a 
reliable marker for Insulin Resistance in 
type 2 diabetes. Tajiri et al.22 used the 
hyperinsulinemic-euglycemic clamp to 
quantify Glucose Infusion Rate (GIR) as an 
index for insulin sensitivity in 16 patients 
with type 2 diabetes. GIR was most strongly 
correlated with circulating Adiponectin 
levels and fasting plasma glucose. 
The role of Adiponectin in mitigating 
insulin resistance has been further 
substantiated by studies in humans and mice 
with lipodystrophies.[23], [24] 
Lipodystrophies are characterized by 
selective but variable loss of body fat and 
insulin resistance. Serum Adiponectin levels 
are extremely low in patients with 
generalized lipodystrophies and may be 
related to the general absence of adipose 
tissue and/or associated severe insulin 
resistance. 
Adipose tissue expression and 
circulating Adiponectin concentrations have 
also been found to be significantly decreased 
in HIV-positive patients with lipodystrophy 
treated with highly active antiretroviral 
therapy. Thus, it may be reasonable to 
surmise that decreased production of 
Adiponectin in lipoatrophic adipose tissue 
may contribute to the development of 
insulin resistance in these patients. 
Visceral fat appears to be an 
important link between the many facets of 
the metabolic syndrome, including glucose 
intolerance, hypertension, dyslipidemia, and 
insulin resistance.[25] Visceral adiposity is 
characterized by enhanced lipolysis and 
augmented plasma FFA flux, especially into 
the portal circulation. Increased inflow of 
FFAs into the liver from the portal 
circulation is thought to retard insulin 
clearance and to enhance lipid synthesis, 
which may result in peripheral 
hyperinsulinemia and hyperlipidemia. FFAs 
have also been shown to induce hepatic 
insulin resistance by inhibiting insulin 
suppression of glycogenolysis during 
euglycemic-hyperinsulinemic clamp studies 
and to directly stimulate glycogenolysis and 
gluconeogenesis, thus contributing to mild 
fasting hyperglycemia in euglycemic subjects 
given lipid infusions.[26] 
Adiponectin mRNA and protein levels 
have been found to be reduced in omental 
fat compared with subcutaneous fat. Visceral 
fat may also produce an as-yet-unidentified 
factor that destabilizes Adiponectin 
mRNA.[27] The inverse correlation between 
serum Adiponectin levels and intra-
abdominal fat mass hints at a strong link 
between visceral fat and insulin resistance. 
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Although Adiponectin is secreted 
only from adipose tissue, its levels are 
paradoxically lower in obese than in lean 
humans. This is in contrast to most other 
adipocytokines, whose levels are increased 
in obesity in proportion to an increased total 
body fat mass. It is possible that although 
Adiponectin expression is activated during 
adipogenesis, a feedback inhibition on its 
production occurs during the development 
of obesity. 
 Adiponectin in Cardiovascular 
diseases 
The potential role of adiponectin in 
cardiovascular diseases has been observed 
in patients with coronary artery diseases 
(CAD), as they have lower levels of 
adiponectin irrespective of ethnic group.[28]  
Intriguingly, HWM adiponectin has been 
linked to CAD. However, the hexamers are 
not affected and trimers increase, 
underlining the importance of HMW 
adiponectin in CAD in addition to the other 
obesity-related disorders/diseases, perhaps 
due to the functional priorities and tissue 
specificity shown by the adiponectin 
isoforms.[29]  
Adiponectin deficiency in ischaemia-
reperfusion mice caused myocardial infarct 
and aggravation was up to 78%, with a surge 
in TNFα levels and a decrease in activation 
of AMPK activity. It should be noted here 
that mice deficient in adiponectin suffer 
from myocardial ischaemia and injury due to 
reduced levels of cyclooxygenase-2 (COX-2), 
suggesting that adiponectin regulates COX-2 
production.[30]  
A possible role of adiponectin in 
atherosclerosis has been observed, in which 
activated macrophages attach to the 
vascular walls and convert into foam cells. 
These cells mass lipid droplets and recruit 
other macrophages to the site, ultimately 
leading to localized inflammation. Adhesion 
of monocytes to human aortic endothelial 
cells (HAECs), facilitated by TNFα, is 
inhibited by adiponectin by reducing the 
expression of vascular cell adhesion 
molecule-1 (VCAM-1), E-selectin, and 
intercellular adhesion molecule-1 (ICAM-1) 
on the surface of HAECs.[31]  
 Some findings suggest a role of 
adiponectin in atherosclerosis by inhibiting 
binding of LDL to biglycan, which is a 
vascular proteoglycan. This ultimately 
decreases lipid accumulation in the 
subendothelial space, the cause of 
atherosclerotic plaque formation.[32]  
In addition, single nucleotide 
polymorphisms (SNPs) at position +276 in 
the adiponectin gene have been associated 
with CAD. T/T homozygous is at a lower risk 
of developing CAD than G/G or G/T variants 
of the genes. A “C” to “G” variant at position 
11,377 in the promoter region of 
adiponectin has been linked to coronary 
atherosclerosis and other related diseases. 
T-cadherin expression is higher in athero-
resistant than atherosclerosis susceptible 
coronary arteries, which indicates that its 
expression is involved in the progression of 
atherosclerosis.[33] Both T-cadherin and 
adiponectin have been found in the vicinity 
of injured vessels, which suggests that they 
have a role in atherosclerosis. 
Paradoxically, recent studies have 
determined that adiponectin has 
cardioprotective effects owing to its anti-
inflammatory, anti-oxidant and anti-
apoptotic properties. Further findings 
suggest that locally produced adiponectin in 
cardiomyocytes are functional and 
biologically significant. The ectopic derived 
adiponectin exerts its protective effects 
through the autocrine mechanism. 
Some of the scientific proofs are: 
Matsubara et al.[34] demonstrated that 
plasma adiponectin concentrations were not 
only inversely related to triglyceride levels, 
atherogenic index (total:HDL cholesterol), 
and apolipoproteins (apos) B and E, but also 
positively correlated to serum HDL 
cholesterol and apo A-1 in nondiabetic 
female patients. These findings suggest that 
the hypoadiponectinemia observed in 
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dyslipidemia may accelerate the 
atherosclerotic changes. 
Severe neo-intimal thickening and 
increased proliferation of vascular smooth 
muscle cells has been demonstrated in 
mechanically injured arteries of adiponectin 
knockout mice. Supplementation of 
adiponectin in this mouse model attenuated 
the neointimal proliferation.[35] This has 
been the first in vivo evidence that 
adiponectin might serve as a critical link 
bridging the adipose tissue-vascular axis. 
High-sensitive C-reactive protein (hs-
CRP) is a well-known marker and risk factor 
for coronary artery disease. It was recently 
shown that CRP mRNA is expressed in 
human adipose tissue. A significant inverse 
correlation has been observed between CRP 
and adiponectin mRNA levels in 
subcutaneous adipose tissue of human 
subjects with angiographically 
demonstrated coronary atherosclerosis[36]. 
This reciprocal association between 
adiponectin and CRP levels in both human 
adipose tissue and plasma is supportive of a 
role for adiponectin against the development 
of atherosclerosis and vascular 
inflammation. 
Levels of Adiponectin are also lower 
in patients with essential hypertension [37] 
and in diabetic patients compared with 
nondiabetic subjects, and are particularly 
low in subjects with CAD. Decreased levels 
are found in men compared with women 
which may be androgen induced[38]. The 
incidence of cardiovascular death has been 
found to be higher in patients with renal 
failure who have decreased adiponectin 
levels (hypoadiponectinemia). [39] 
 Adiponectin in Cancer 
Studies have shown that individuals 
with low levels of adiponectin 
(hypoadiponectinaemia) could be at higher 
risk of developing malignancies linked to 
obesity, insulin resistance, endometrial 
cancer, postmenopausal breast cancer, 
leukaemia, colon, gastric, and prostate 
cancer.  
The conditions like polycystic ovary 
syndrome (PCOS) can also result due to 
hypo levels of adiponectin. PCOS is 
characterized by hyperandrogenism, where 
high levels of circulating insulin stimulate 
the ovary to produce more androgens and 
decreases the production of Sex Hormone 
Binding Globulin (SHBG), leading to an even 
higher hyperandrogenic state.[40] This 
confers the low level of adiponectin, 
inversely proportional to that of insulin. 
 Also, the expression of adiponectin 
receptors in lung tissues was apparent 
particularly in the areas of cancerous lesions 
(64.2% AdipoR1 and 61.9% AdipoR2). [41]  
As Adiponectin modulates several 
intracellular signaling pathways and 
stimulates AMPK, PPARγ, and MAPK in 
insulin target organs such as the liver and 
skeletal muscles, it can inhibit cancer 
progression and invasion through its 
receptors (AdipoR1, AdipoR2). [42] 
 Adiponectin in Non-Alcoholic Fatty 
Liver Disease (NAFLD) 
NAFLD encompasses a spectrum of 
conditions associated with lipid deposition 
in hepatocytes. It ranges from steatosis / 
Non alcoholic fatty liver (NAFL / simple fatty 
liver), to Non Alcoholic Steato Hepatitis 
(NASH—fatty changes with inflammation 
and hepatocellular injury or fibrosis), to 
advanced fibrosis and cirrhosis. NAFLD is 
characterized by insulin resistance and is 
associated with metabolic risk factors such 
as obesity, diabetes mellitus, and 
dyslipidemia.  
Serum adiponectin level has been 
found to be significantly lower in the early-
stage NASH group compared to the simple 
steatosis group (P <0.001).[43]  
In the liver, adiponectin acts through 
the activation of the AMPK and PPAR-α 
pathways and inhibition of toll-like receptor-
4 mediated signaling.[44] It is believed that 
adiponectin attenuates liver inflammation 
and fibrosis, possibly through the decrement 
in the hepatic and insulin resistance.  
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Adiponectin is considered to have 
insulin sensitizing, antifibrogenic, and anti-
inflammatory properties by acting on 
hepatocytes, hepatic stellate cells, and 
hepatic macrophages (Kupffer cells), 
respectively. Adiponectin decreased 
gluconeogenesis, decreased free FFA influx 
into the liver, and increased FFA oxidation. 
In addition, adiponectin has antifibrotic 
action in the liver, mainly through down-
regulating the expression of aldehyde 
oxidase, TGF and CTGF, and anti-
inflammatory action by suppressing TNF-α 
and other proinflammatory cytokines and by 
inducing anti-inflammatory cytokines, such 
as IL-10.[45] 
ADIPONECTIN: CLINICAL ASSOCIATION 
Genetic studies have mapped a 
susceptibility locus for type Metabolic 
Syndrome, 2 diabetes, and Coronary Heart 
Disease to Chromosome 3q27, where the 
gene encoding Adiponectin is located.[46]  
Hara et al. found that genetic 
variations resulting in reduced serum 
adiponectin levels are associated with 
increased risk for type 2 diabetes.[47] In 
another study, Japanese subjects carrying a 
mis-sense mutation in the adiponectin gene 
associated with hypoadiponectinemia 
exhibited the phenotype of the metabolic 
syndrome, including Insulin Resistance and 
Coronary Artery Disease. Thus genetic 
polymorphisms of the adiponectin gene that 
result in lower production and secretion of 
adiponectin may be responsible, at least in 
part, for the pathogenesis of the various 
metabolic pathologies. 
Improvement in insulin sensitivity by 
weight reduction in obese subjects with 
gastric bypass surgery [48] has been reported 
to increase adiponectin levels. In view of its 
potential beneficial effects, any measure that 
increases adiponectin levels would likely 
have therapeutic significance. In addition to 
hypolipidemic and antidiabetic effects, the 
therapeutic advantages of adiponectin 
include potential anti-inflammatory 
properties that might prevent or retard 
Atherogenesis, without increasing body 
weight. 
Hence, replenishment of adiponectin 
clearly represents a novel treatment strategy 
for insulin resistance and related metabolic 
diseases. 
ADIPONECTIN: APPLICATION OF 
AYURVEDIC HERBS 
The following herbs considered for 
the scientific review are a part of Extra-
Mural Project conducted in National 
Institute of Ayurveda, Jaipur, Rajasthan. 
Apart from their therapeutic effect on blood 
glucose and lipid levels, these drugs were 
found to have cumulative positive feedback 
effect on the basal metabolism and 
constitution of the subject with improved 
levels of Adipocytokines, particularly 
Adiponectin.  
Haridra (Curcuma longa) 
Curcumin helps lower 
inappropriately high levels of leptin 
(reducing leptin resistance) while boosting 
the all-important levels of the adiponectin 
(which lowers insulin resistance). The study 
conducted by Somlak et. al., on the extract of 
curcuma longa in type II Diabetes mellitus 
revealed that Curcumin intervention 
significantly increased adiponectin levels.[49] 
In another study where abdominal 
subcutaneous adipose tissue and perirenal 
adipose tissue were collected from the 
operating-patients were cultured for 6 and 
24 hours with different concentrations of 
curcumin (10 and 100 μg/ml) in vitro, 
revealed that 100 μg/ml curcumin can 
increase adiponectin secretion and decrease 
IL-6 secretion in human adipose tissues 
cultivated in vitro.[50] 
Curcumin also prevents High Fat Diet 
Induced Insulin Resistance and Obesity via 
Attenuating Lipogenesis in Liver and 
Inflammatory Pathway in Adipocytes.[51] 
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Amalaki (Emblica officinalis) 
T.P. Rao et.al., stated the medicinal 
qualities of Amla that it significantly 
improves the serum adiponectin levels.[52]  
K.H. Khan stated that Amla extracts 
orally administered to the diabetic rats 
slightly improved body weight gain and also 
significantly increased various oxidative 
stress indices of the serum of the diabetic 
rats along with a significant increase in 
serum adiponectin levels.[53] 
As deduced by Islam, Aminul. et al. 
Thiobarbituric acid-reactive substance levels 
were significantly reduced with Emblica 
officinalis extract, indicating a reduction in 
lipid peroxidation. With this, the serum 
adiponectin levels also improved 
significantly.[54] 
Pippali (Piper nigrum) 
Following the studies of Zhang H 
et.al., it is understood that Several amide 
constituents (piperlonguminine and 
retrofractamides A, B, and C) from the fruit 
of Piper promoted adipogenesis of 3T3-L1 
cells. Among them, retrofractamide A was 
the most active and significantly increased 
the amount of adiponectin released into the 
medium and the uptake of 2- deoxyglucose 
into the cells. Retrofractamide A also 
increased mRNA levels of adiponectin, 
peroxisome proliferator-activated receptor 
gamma2 (PPARgamma2), glucose 
transporter 4 (GLUT4), and insulin receptor 
substrate 1 (IRS-1), but did not act as a 
PPARgamma agonist different from 
troglitazone.[55] 
Pushkaramula (Inula racemosa) 
Insulin can produce its effect on 
blood glucose level, insulin and lipid profile 
through its ability to change the blood level 
of adipocytokines.[56] 
Guduchi (Tinospora cordifolia) 
Choi, Bong-Hyuk et.al., during their 
study on the inhibition of inflammatory 
molecule expression discovered that 
Berberine in Tinospora cordifolia prevents 
and suppresses proinflammatory 
cytokines, E-selectin and genes, and 
increases adiponectin expression.[57]  
Musta (Cyperus rotundus) 
Pharmacological studies by 
Mahishankar, Dharashive Vishweshwar on 
the effect of aqueous extracts of Cyperus 
rotundus Linn. on plasma Adiponectin levels 
and glucose tolerence in diet fed obese 
Wistar rats revealed that the improved 
levels of serum adiponectin helped in 
regulating the normal levels of glucose.[58] 
Aardrak (Zingiber officinale) 
Insulin sensitizing is an important 
therapeutic mechanism against NAFLD, 
where the key role in the pathology is of 
insulin resistance and resulting 
hyperinsulinemia with hepatic triglyceride 
accumulation,. A previous preliminary study 
reported that the insulin sensitivity to 
adipocytes could be improved using ginger, 
with gingerol as its active component for this 
effect.[59] 
PPARγ agonists have been 
hypothesized to be of therapeutic 
importance in NAFLD and ginger’s 6-Shogaol 
has been reported to be a significant agonist 
of PPARγ in adipocytes.[60] 
CONCLUSION 
The correlations between 
hypoadiponectinaemia, Insulin Resistance, 
Dyslipidaemia and Cardiovascular diseases 
are well established from various 
researches. Owing to its pleiotropic effects 
as a biomarker in different systemic 
pathologies, Adiponectin has the potential to 
become a clinically relevant parameter to be 
considered for the evaluation of metabolic 
diseases. 
Adiponectin administration as well as 
regulation of the pathways controlling its 
metabolism, represents a promising target 
for managing the aforementioned metabolic 
pathologies. In this regard Ayurvedic herbs 
were found to provide a serious contribution 
to the homoeostasis of adipocytokines, 
specifically Adiponectin, for curbing 
metabolic pathologies.  
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